SCYNEXIS (FRA:135) Cyclically Adjusted Revenue per Share: €5.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:135 SCYNEXIS Inc FRA:135
40 GF Score
Price €4.36
GF Value €14.60
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Cyclically Adjusted Revenue per Share?

SCYNEXIS FRA:135 +1.40% 40 Cyclically Adjusted Revenue per Share is €5.14 as of Jun. 2026. GuruFocus rates FRA:135 with a GF Score™ of 40/100 and a GF Value™ of €14.60. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SCYNEXIS's adjusted revenue per share for the three months ended in Jun. 2026 was €0.017. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, SCYNEXIS's average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -68.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of SCYNEXIS was -68.20% per year. The lowest was -68.20% per year. And the median was -68.20% per year.

As of today (2026-08-16), SCYNEXIS's current stock price is €4.355. SCYNEXIS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €5.14. SCYNEXIS's Cyclically Adjusted PS Ratio of today is 0.85.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SCYNEXIS was 3.70. The lowest was 0.07. And the median was 1.26.


SCYNEXIS  (FRA:135) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SCYNEXIS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.355/5.14
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SCYNEXIS was 3.70. The lowest was 0.07. And the median was 1.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SCYNEXIS Cyclically Adjusted Revenue per Share Related Terms


SCYNEXIS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for SCYNEXIS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS Cyclically Adjusted Revenue per Share Chart

SCYNEXIS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 120.68 11.69 3.29 3.66

SCYNEXIS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.64 3.66 0.00 5.14

FRA:135 vs IXHL, ETST, INIS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PS Ratio falls into.


FRA:135
40GF Score
SCYNEXIS Inc FRA:135
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SCYNEXIS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SCYNEXIS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.017/333.9520*333.9520
=0.017

Current CPI (Jun. 2026) = 333.9520.

SCYNEXIS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.195 241.428 0.270
201612 0.202 241.432 0.279
201703 0.188 243.801 0.258
201706 0.176 244.955 0.240
201709 0.159 246.819 0.215
201712 0.150 246.524 0.203
201803 0.124 249.554 0.166
201806 0.094 251.989 0.125
201809 0.094 252.439 0.124
201812 0.093 251.233 0.124
201903 0.093 254.202 0.122
201906 0.075 256.143 0.098
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 3.053 264.877 3.849
202106 0.000 271.696 0.000
202109 0.127 274.310 0.155
202112 0.156 278.802 0.187
202203 0.150 287.504 0.174
202206 0.231 296.311 0.260
202209 0.265 296.808 0.298
202212 0.242 296.797 0.272
202303 0.177 301.836 0.196
202306 19.444 305.109 21.282
202309 0.276 307.789 0.299
202312 0.887 306.746 0.966
202403 0.208 312.332 0.222
202406 0.113 314.175 0.120
202409 0.098 315.301 0.104
202412 0.153 315.605 0.162
202503 0.039 319.799 0.041
202506 0.190 322.561 0.197
202509 0.046 324.800 0.047
202512 2.516 324.054 2.593
202603 0.000 330.213 0.000
202606 0.017 333.952 0.017

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €5.14 mean?
SCYNEXIS (FRA:135) has a Cyclically Adjusted Revenue per Share of €5.14 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SCYNEXIS and its competitors.
Is SCYNEXIS's Cyclically Adjusted Revenue per Share too high?
SCYNEXIS's current Cyclically Adjusted Revenue per Share is €5.14. Overall, SCYNEXIS has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Cyclically Adjusted Revenue per Share compare to IXHL and ETST?
SCYNEXIS's Cyclically Adjusted Revenue per Share of €5.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current Cyclically Adjusted Revenue per Share is €5.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
SCYNEXIS (FRA:135) has a current Cyclically Adjusted Revenue per Share of €5.14. The stock's GF Value™ is €14.60, compared to a current price of €4.36 — trading 70.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €5.14. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For SCYNEXIS (FRA:135), the current Cyclically Adjusted Revenue per Share is €5.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (FRA:135) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of €4.36 is trading 70.2% below its estimated GF Value™ of €14.60.

Key valuation signals for FRA:135:

  • Cyclically Adjusted Revenue per Share: €5.14
  • GF Value™: €14.60 vs. price of €4.36 (70.2% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SCYNEXIS Business Description

Other Exchanges SCYX:USA0L49:UK135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score

Get the complete analysis for FRA:135

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.36
Price
€14.60
GF Value